Neurocrine acquires Soleno for $2.9B: what the deal signals about the 2026 M&A wave Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash. The deal is Neurocrine’s largest acquisition ever and adds Vykat XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, to its rare disease […]
AI in pharmaceutical manufacturing quality: from reactive QC to predictive control Pharmaceutical manufacturing quality control has operated on the same fundamental model for decades. Collect samples at defined intervals. Test in the laboratory. Release or reject the batch. Wait 48 to 72 hours for results. AI is dismantling this model. Not incrementally. Structurally. Sanofi’s CEO
AI in pharmaceutical manufacturing quality: from reactive QC to predictive control Read More »
Anthropic acquires Coefficient Bio for $400M: what it means for AI drug discovery Anthropic has acquired Coefficient Bio, an AI biotech startup with fewer than 10 employees, for over $400 million in stock. The company had been operating in stealth for just eight months. It had no publicly disclosed product and no commercial revenue. The
Anthropic acquires Coefficient Bio for $400M: what it means for AI drug discovery Read More »
AI cold chain optimisation for biologics: how to stop losing product to temperature excursions A single temperature excursion on a biologic shipment can write off product worth hundreds of thousands of dollars. At scale, across a global distribution network, the losses are structural. The biologics cold chain has always been the most operationally complex part
AI key account management in biotech: from relationship tracking to revenue intelligence Most biotech key account management runs on structured relationships and manual updates. Account plans are written once a quarter. CRM entries are filed after the call. Insights arrive weeks after the conversation. AI changes this. Not by replacing the account manager, but by
AI key account management in biotech: from relationship tracking to revenue intelligence Read More »
The 2025 Drug Sales Ranking Is a Commercial Disruption Map Keytruda held the top spot at $31.7 billion. Mounjaro came in second at $23 billion. Humira, once the world’s best-selling drug at $21 billion, closed 2025 at $4.5 billion. Most people read this ranking as a sales leaderboard. Our team at AIxBiotech reads it as
The 2025 Drug Sales Ranking Is a Commercial Disruption Map Read More »
AI Launch Strategy in Emerging Markets: Why the Playbook That Works in the EU5 Fails Everywhere Else The EU5 launch model assumes things that do not exist in emerging markets. Structured reimbursement timelines. Published HTA criteria. Standardised payer processes that experienced market access teams can navigate from precedent. Emerging markets in Central and Eastern Europe,
AI Launch Strategy in Emerging Markets: Beyond the EU5 Playbook Read More »
AI Patient Recruitment Optimization in Clinical Trials: Fixing the Problem That Kills Half Your Development Timeline Eighty percent of clinical trials fail to meet their recruitment targets. Nearly a third of all Phase III studies fail to enroll a single patient on time. Recruitment delays extend trial timelines by an average of six to eight
AI Patient Recruitment Optimization: Fix the Problem That Kills Half Your Timeline Read More »
One Injection Restored Hearing in Every Patient. What Gene Therapy Just Did to the Rare Disease Market A single injection. Ten patients. Every one of them heard sounds they had never heard before. This is not a promising early result. This is a signal the rare disease commercial model is about to change. Slide 1
One Injection Restored Hearing in Every Patient. What Gene Therapy Just Changed. Read More »
The FDA approved Foundayo (orforglipron) by Eli Lilly on April 1 2026 as a once-daily oral GLP-1 for obesity. With no food restrictions, small-molecule manufacturing, $25 monthly pricing with insurance, and a DTC launch through LillyDirect, Foundayo resets access and distribution assumptions across the entire GLP-1 market. Analysts forecast $14.79 billion in sales by 2030.
Lilly’s Foundayo FDA Approval Resets the GLP-1 Commercial Playbook Read More »
